BioMedNewsBreaks

WednesdayMay 20, 2026 9:00 am

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Proposed Public Offering of Common Stock and Warrants

Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing buntanetap for neurodegenerative diseases, announced a proposed underwritten public offering of common stock and accompanying warrants. The company intends to use net proceeds to support continued clinical development of buntanetap in a Phase 3 Alzheimer’s disease study, as well as for working capital and general corporate purposes. To view the full press release, visit https://ibn.fm/1cxGA About Annovis Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's…

Continue Reading

TuesdayMay 19, 2026 2:28 pm

BioMedNewsBreaks — MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Advancing Workplace Safety with AI-Powered Technology

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) is introducing a novel system aimed at identifying drug and alcohol impairment, initially focused on the South American mining sector, where remote operations and heavy machinery make safety monitoring critical. An article discussing this reads, “The biotechnology company, which has spent several years conducting research into intoxication detection, has developed a voice-based AI system designed to identify signs of alcohol or drug impairment within seconds, the first of its kind in the world. Instead of relying on traditional biological testing methods…

Continue Reading

TuesdayMay 19, 2026 1:58 pm

BioMedNewsBreaks — Oncotelic Therapeutics Inc. (OTLC) Expands Beyond Biotech with AI-Enhanced Robotics Strategy

Oncotelic Therapeutics (OTCQB: OTLC) is moving beyond its roots as a clinical-stage biotechnology company into the quickly expanding intersection of artificial intelligence and industrial automation. “Through two closely aligned announcements, the firm has unveiled a strategic partnership with TechForce Robotics, which positions it to commercialize a next-generation, AI-enhanced platform created for regulated pharmaceutical environments,” reads a recent article. “At the core of this pivot is Oncotelic’s proprietary PDAOAI platform, an AI-driven system designed to improve compliance, monitoring, and operational intelligence. By integrating this innovation with TechForce Robotics’ hardware and manufacturing expertise, the companies aim to deliver a GMP-compliant robotics solution capable…

Continue Reading

TuesdayMay 19, 2026 11:02 am

BioMedNewsBreaks — CEL-SCI Corporation (NYSE American: CVM) Closes $7.2 Million Public Offering 

CEL-SCI Corporation (NYSE American: CVM) announced the closing of its best-efforts public offering of 6 million shares of common stock priced at $1.20 per share, resulting in gross proceeds of approximately $7.2 million before fees and expenses. The company said net proceeds will be used to support continued development of Multikine(TM), as well as for general corporate purposes and working capital. To view the full press release, visit https://ibn.fm/pDJVA About CEL-SCI Corporation CEL-SCI believes that boosting a patient’s immune system before surgery, radiotherapy and chemotherapy have damaged it, should provide the greatest possible impact on survival. Multikine is designed to help the immune system "target" the…

Continue Reading

MondayMay 18, 2026 9:50 am

BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Highlights Phase IIa Progress and Strategic CNS Expansion Plans

Oragenics (NYSE American: OGEN) provided a shareholder update outlining progress in its Phase IIa clinical trial of ONP-002 for concussion and mild traumatic brain injury in Australia, with active patient enrollment and dosing underway across multiple sites, while advancing U.S. regulatory preparations targeting a Type C FDA meeting request in the second quarter and IND submission by year-end 2026. The company also disclosed a letter of intent to pursue licensing of a complementary CNS-related medical device and reported a March 31, 2026, cash balance of $6.1 million. To view the full press release, visit https://ibn.fm/tEk2C About Oragenics, Inc. Oragenics, Inc.…

Continue Reading

MondayMay 18, 2026 9:20 am

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reports Midpoint Enrollment Milestone in Multiple Sclerosis Imaging Study

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that patient enrollment in its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached the halfway mark, with preliminary imaging data showing encouraging signal in acute MS lesions and potential sensitivity to gray matter lesions. The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination, which the company believes could enhance development of MS therapies including its investigational candidate Lucid-MS, for which an IND submission for a Phase 2…

Continue Reading

FridayMay 15, 2026 1:21 pm

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Subsidiary Active Intelligence to Showcase Wellness Products at ECRM Conference 

Nutriband (NASDAQ: NTRB) announced that its wholly owned subsidiary, Active Intelligence, will participate in the June 2026 ECRM conference, where it plans to showcase its expanding portfolio of wellness, recovery and performance-focused consumer products to buyers from major retail, pharmacy and healthcare organizations. The company will feature its existing AI Tape line and introduce new products including AI Performance Tape, AI Energy Patches and AI Sleep as it seeks to expand retail partnerships and distribution opportunities. To view the full press release, visit https://ibn.fm/MdpEg About Nutriband Inc. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA(TM) abuse-deterrent…

Continue Reading

FridayMay 15, 2026 12:05 pm

BioMedNewsBreaks — MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Featured in NetworkNewsAudio Editorial on Voice-Based Intoxication Detection

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising.  MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) was featured in a NetworkNewsAudio audio press release highlighting the emerging potential of AI-powered voice analysis as a noninvasive method for intoxication detection. The editorial explores how speech-based diagnostics may offer rapid, real-time assessment of cognitive and physiological impairment by analyzing measurable vocal biomarkers such as tone, pitch, rhythm and articulation. To view the full press release, visit https://ibn.fm/KxB4E About MindBio Therapeutics Corp. MindBio is a biotechnology company that is commercialising AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to…

Continue Reading

FridayMay 15, 2026 12:02 pm

BioMedNewsBreaks — Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Poised at Intersection of Precision Medicine, Preventive Care

Cardio Diagnostics Holdings (NASDAQ: CDIO), a precision medicine company leveraging epigenetics, genetics and artificial intelligence, is poised to meet demands as cardiovascular disease continues to place a profound burden on individuals, economies and healthcare systems worldwide. “Cardio Diagnostics is committed to reducing the impact of heart disease by developing a platform that integrates artificial intelligence and epigenetic and genetic biomarkers to deliver personalized cardiovascular insights from a simple blood sample, positioning itself at the intersection of precision medicine and preventive care,” reads a recent article. “Cardio Diagnostics is addressing this need through its proprietary platform, which combines artificial intelligence with multi-omic biomarker analysis. The…

Continue Reading

FridayMay 15, 2026 11:53 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsAudio Editorial on CNS Drug Delivery Innovation 

Oncotelic Therapeutics (OTCQB: OTLC) was featured in a NetworkNewsAudio audio press release focused on emerging opportunities in central nervous system drug delivery, highlighting the challenges posed by the blood-brain barrier and the company’s efforts to advance technologies designed to overcome those limitations. The editorial also noted Oncotelic’s recent strategic monetization agreement with Lunai Bioworks involving its N2B delivery system, supporting initiatives in biodefense and Alzheimer’s disease treatment. To view the full press release, visit https://ibn.fm/ySesO About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The Company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic…

Continue Reading